A 28-year-old woman from Kerala presents with jaundice, dark urine, and pallor. On examination, splenomegaly is noted. Laboratory findings show Hb 8.5 g/dL, reticulocyte count 12%, indirect bilirubin 4.2 mg/dL, and a positive direct antiglobulin test (DAT). Peripheral blood smear shows spherocytes. She denies recent transfusions, infections, or drug use. What is the most appropriate next step in management?

Explanation

## Clinical Diagnosis This patient presents with **autoimmune hemolytic anemia (AIHA)**, evidenced by: - Positive DAT (direct antiglobulin test) — hallmark finding - Spherocytes on blood smear - Elevated reticulocyte count and indirect hyperbilirubinemia - No history of transfusion or recent infection (ruling out secondary causes) ## Management Algorithm for AIHA ```mermaid flowchart TD A[Positive DAT + Hemolysis]:::outcome --> B{Severity & Response?}:::decision B -->|Mild/Compensated| C[Observation + Folic acid]:::action B -->|Moderate/Symptomatic| D[Corticosteroids first-line]:::action D --> E{Response at 2-4 weeks?}:::decision E -->|Yes| F[Taper steroids]:::action E -->|No| G[Add steroid-sparing agent or splenectomy]:::action B -->|Severe/Life-threatening| H[Steroids + IVIG/Transfusion]:::urgent ``` ## Why Corticosteroids Are First-Line **Key Point:** Corticosteroids (prednisolone 1 mg/kg/day) are the **gold standard initial treatment** for AIHA because they: 1. Suppress antibody production by B cells 2. Reduce macrophage Fc-receptor expression in the spleen 3. Achieve response in 70–80% of patients within 2–4 weeks 4. Are safer than splenectomy as a first step **High-Yield:** Response to steroids is defined as: - Hb rise ≥2 g/dL, OR - Reticulocyte count normalization, OR - Clinical improvement (jaundice resolution, energy return) ## Why Other Options Are Premature | Option | Why Not First | Timing | |--------|---------------|--------| | Osmotic fragility test | Tests for hereditary spherocytosis (HS), not AIHA. HS is DAT-negative. | After ruling out HS if DAT is negative | | IVIG | Reserved for severe, steroid-refractory, or life-threatening hemolysis. | Second-line or emergency use | | Splenectomy | Effective but invasive; reserved for steroid-dependent or steroid-resistant cases. | After 2–4 weeks of steroid trial | **Clinical Pearl:** This patient is stable (Hb 8.5 g/dL, no cardiopulmonary compromise), so corticosteroids alone are appropriate. IVIG and transfusion are reserved for acute, severe presentations. **Warning:** Do not confuse AIHA with hereditary spherocytosis — HS is DAT-negative and has a family history; AIHA is DAT-positive and acquired.